Overview

Apremilast acts through phosphodiesterase-4 (PDE4) inhibition, a mechanistic route distinct from biologics or broad immune suppressants, which explains its fit as an oral option in psoriasis and psoriatic arthritis. APORES delivers apremilast 10 mg tablets in 60-tablet boxes aligned to the labelled titration pack. This article details the intracellular pathway by which the drug dampens inflammatory signalling, and why a controlled escalation schedule is built into therapy. Understanding the mechanism clarifies both its benefits and its characteristic titration nausea.

How It Works

Inside immune and keratinocyte cells, PDE4 normally breaks down cyclic AMP, an intracellular messenger that restrains inflammatory gene expression. Apremilast inhibits PDE4, raising cAMP levels and thereby reducing the production of tumour necrosis factor-alpha, interleukin-23, and other mediators driving psoriatic inflammation. The effect is intracellular and immunomodulatory rather than cytotoxic. Because the pathway is downstream of many upstream triggers, PDE4 blockade moderates inflammation broadly without eliminating specific immune cell populations, a profile that suits long-term oral use.

Indications

Apremilast is indicated for adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy, and for active psoriatic arthritis. The 60-tablet pack supports the titration and maintenance phases. It is valued for patients who prefer oral treatment or who are unsuitable for biologics or methotrexate. Prescribers initiate therapy with a step-up schedule to limit early gastrointestinal intolerance.

Dosage & Administration

Treatment starts at 10 mg once daily and escalates by 10 mg per day over five days to the maintenance dose of 30 mg twice daily, following the labelled titration table. Tablets are swallowed whole with or without food. A 60-tablet box covers early titration plus initial maintenance. If a dose is missed, it is skipped rather than doubled, and the regular schedule resumes.

Storage & Sourcing

Store below 30°C in the original blister, away from moisture and light. Apremilast is prescription-only; B2B orders require licensed sourcing and market authorisation. Because the titration pack dictates the first-week sequence, buyers should stock sufficient 10 mg starter quantities alongside maintenance strengths. Verify batch expiry and certificate of analysis on receipt, and align inventory with outpatient cohorts tolerating oral systemic therapy.

FAQ

Q: How does PDE4 inhibition reduce psoriasis inflammation? A: By blocking PDE4, apremilast raises intracellular cAMP, which lowers production of TNF-alpha and IL-23 that drive psoriatic plaques and joint inflammation.

Q: Why does therapy begin at 10 mg and step up? A: The five-day escalation limits early nausea and diarrhoea, the most common transient effects of PDE4 blockade, before reaching the 30 mg maintenance dose.

Q: Is apremilast an immunosuppressant like methotrexate? A: No. It modulates intracellular signalling without broadly suppressing cell populations, which is why it is often chosen when conventional immunosuppressants are unsuitable.